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Abstract
The dengue virus is a member of vector-borne diseases that causes zoonotic disease
and spreads rapidly in the world. No single treatment or vaccine yet is available that
is recommended and there is no correlation with protectiveness against this disease.
The heavy chain (VH) and light chain (VL) variables are molecules of immunoglobulin
G (IgG) is the smallest part of the antibody. Although the part-time domain variable
is short, it can be used as a long-term and rapid immune booster in the immune
system. In this study we tried to clone an encoding gene that was able to influence
the adaptive immune response to dengue 1-4 by using MSC as a gene carrier. The
target scFv-IgG gene has been successfully integrated into the plasmid. Plasmids that
we have linearly transfected into the MSC. From the cDNA synthesis results continued
with PCR synthesis with primer FGHV and RGHA obtained bands in accordance with
the target of 404 bp. The scFv gene encoding IgG can be integrated with MSC.
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1. Introduction
The dengue virus is a vector-borne diseases that causes zoonotic disease and spreads
rapidly in the world [1, 2]. No single treatment or vaccine is available that is recom-
mended and there is no correlation with protectiveness against the disease. Neu-
tralization tests were not able to distinguish between specific serotypes and cross-
immune antibodies in patients at the onset of infection, which led to overestimation
of the long-term serotype antibody response.
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Hybridoma and genetic engineering technologies can be used by utilizing and re-
modifying individual antibodies obtained from immunized individuals [3].
The heavy chain (VH) and light chain (VL) variables are molecules of the
immunoglobulin G (IgG) is the smallest part of the antibody. Although the part-time
domain variable is short, it can be used as a long-term and rapid immune booster in
the immune system.
Cell-based therapy has improved significantly over the last few decades and is
poised to become a major pillar of modern medicine. Recent studies have shown that
these cells have large immune modulation capacities [4]. Mesenchymal stem cells
have immunomodulatory properties on some lineages such as T cells and B regulators.
Mesenchymal stem cell (MSC) has also been shown to possess extensive immunoreg-
ulation abilities and be able to cope with adaptive and innate immune responses. MSC
inhibits proliferation andmaturation of immune cells and suppresses immune reactions
both in vitro and in vivo [5].
Genetic stem cells can be modified to express intact antibody fragments or single
chain antibody fragments (scFv) [6]. MSC has also has been investigated as a carrier
medium for antibody delivery. In human MSC studies have been carried out nucleo-
physics to be able to express scFv on its cell surface against glioma III (EGFRvIII) [7].
This platform is able to function to express a series of antigen-specific paratops.
In this study we tried to clone a coding gene that was able to influence the adaptive
immune response to dengue 1-4 by using MSC as a gene carrier. Cellular response to
dengue virus initiated MHC I and MHC II bonds on CD4 + and CD8 + T cells. Activation
of some of these cytokines has a greater concentration in DHF patients.
2. Material and methods
TArget Clone (Toyobo,Japan), DH5α cells (Toyobo Life Science, Japan), Lipofectamine
3000 (Carlsbad, CA), Opti-MEM𝑇𝑀 Medium (Gibco, USA), trizol® (Carlsbad, CA), First
Strand cDNA Synthesis Kit (Invitrogen), PCR Reagent System (Carlsbad, CA), 1Kb plus
DNA Markers (Carlsbad, CA), UltraPureTM Agarose (Carlsbad, CA), Zyppy𝑇𝑀 Plasmid
Miniprep Kit (Zymo,USA), SYBR𝑇𝑀 Safe DNA Gel Stain (Carlsbad, CA), Tris Buffer EDTA
0,5x, BlueJuiceTM Gel Loading Buffer (Carlsbad, CA), QIAquick Gel Extraction Kit (Qia-
gen).
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2.1. Mesenchymal stem cellcCulture
Rat MSC obtained from Stem cell Research and Development Center, Airlangga Uni-
versity, Surabaya, Indonesia. Rat mesenchymal stem cell cultured in medium with Dul-
becco’s modified Eagle’s medium (DMEM) and serum fetal bovine (FBS). Non-adherent
cells are released carefully after 3 hours and replaced with fresh media. When the
primary culture becomes almost confluent, culture treats 0.5 ml of 0.25% trypsin con-
taining 0.02% ethylenediaminetetraacetic acid for 2 min at room temperature (25 ∘C).
2.2. Construction and identification of IgG heavy chain genes
Adapted mice treated with multivalent dengue vaccination 1-4 and control were given
PBS at a dose of 0.3 ml each, Injection was performed on days 0, 7, 14, 21 and 28. The
spleen was taken on day 32 after being treated with five vaccinations. Then extracted
RNA using Trizol (Invitrogen) and amplified with primers set GHVF and GHVR.
RNA extraction was performed using TRIzol® Reagent Invitrogen (Allen Way, USA).
Primer for PCR is designed using data from the National Center for Biotechnology
Information (NCBI) site based on the sequence of the Mus musculus immunoglobulin
heavy chain locus constant region of GenBank. Specific primers for IgG heavy chains
are designed using Primary select software. GHVF Primary: 5’AGTGAAGCTTGAGGAGTCT
3’, Primer GHVR: 5’GCTCCTGTTCCTGGTTTAC 3’. The length of the amplified segment is
400 bp.
The PCR product was detected by electrophoresis in 1% agarose gel. Target seg-
ments identified under Ultraviolet lights. Segment gene targets ligation and purifica-
tion by using QIAquick Gel Extraction Kit.
2.3. Cloning scFv-IgG Gene
PCR Product coding scFv-IgG gene then sub Cloning using cassette vector pTA2, mixing
on a 0.2 ml micro tube. 9 μl of the PCR product is fed into a 0.2 ml micro tube, then
added a 0.1 μl 10x A- attachment mix then mixed by gently tapping the tube with
the finger. The tube was incubated in a thermal cycler with a temperature of 60 ∘C 10
minutes. A 5 μl 2x reagent, 1 μl pTA2 (50ng / μl) vector, 3 μl of dA-attached PCR product
and 1 μl T4 DNA Ligase ligation buffer were added. Incubated at room temperature (15-
25 ∘C) was performed in a thermal cyler with a temperature of 20 ∘C for 30 minutes,
then transformed. thenmixed by gently tapping the tube with the finger. The tube was
incubated in a thermal cycler with a temperature of 60 ∘C 10 minutes. A 5 μl 2x reagent,
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Figure 1: Map of plasmid vector.
1 μl pTA2 (50ng / μl) vector, 3 μl of dA-attached PCR product and 1 μl T4 DNA Ligase
ligation buffer were added. Incubated at room temperature (15-25 ∘C) was performed
in a thermal cyler with a temperature of 20 ∘C for 30 minutes, then transformed.
2.4. Transformation
The cultures of E. coli strain BL21 mix & go cells (zymo, USA) were grown on 0.5 L of
LB medium and then grown on 50 ml of ZymoBroth 𝑇𝑀 medium in erlenmeyer. After
completion it is then grown on LB to have ampicillin added 100 μl / ml then incubated
in an incubator at 37∘C for 48 hours according to the manufacturer’s recommended
protocol.
The plasmid is extracted from E.coli bacteria by using Zyppy 𝑇𝑀 Plasmid Miniprep
Kit according to the manufacturer’s recommended protocol (Zymo, USA). The plasmid
restricted by HIND III. Plasmid pTA2 / GHV (1.2 μg) 5 μl, HIND III 1 μl, 10 × Buffer K1 μl,
10 × BSA 2 μl, sterile water added up to 20 μl, cutting was done on dry bath at 37∘C for
4 Hour, then detected by electrophoresis with 1% agarose then the result continued
sequencing.
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Figure 2: Positive clone analysis. Recombinant plasmid digestion product with 1% agarose electrophoresis
shows, red arrow is for target gene fragment, blue arrow for plasmid vector. 1. GHV Control; 2. GHV dengue;
M. Marker 1 kb Plus.
2.5. Transfection MSC
Adapted mice treated with multivalent dengue vaccination 1-4 and control were given
PBS at a dose of 0. In this study used conventional lipofectamine method to transfec-
tion on rat MSC. Briefly, Lipofectamine 3000 (Invitrogen, Carlsbad, CA) is mixed with a
DNA plasmid on Opti-MEM (Invitrogen, Carlsbad, CA) media according to the manufac-
turer’s recommendation. MSC mouse cells were incubated on Opti-MEM medium with
DNA- lipofectamine complex for 6 hours, then media replaced with complete media
that FBS added.
3. Result
To verify the genes we cloned can be integrated with the plasmid vector and have
been transformed to competent E. coli, the plasmids were digest with HINDIII, the
result of restriction was electrophoresis. From the electrophoresis obtained two bands,
targeting cloning and plasmid vectors (fig.2).
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Figure 3: PCR DNA After Transfusion PCR DNA gene encoding scFv-IgG GHV Transfected. 1: Control Group;
2: Dengue Treatment Group; M: 1kb Plus MarkerDiskusi.
The target scFv-IgG gene has been successfully integrated into the plasmid. Plas-
mids that we have linearly transfected into the MSC. After cells confluent reach 90%
we do RNA extraction from MSC cells to find out whether cells can enter the MSC
cell nucleus. RNA was extracted using Trizol (Invitrogen, Carlsbad, CA). RNA obtained
reverse transcription with First Strand cDNA Synthesis Kit (Invitrogen, Carlsbad, CA).
From the cDNA synthesis results continued with PCR synthesis with primary FGHV and
RGHA obtained bands according to the target of 404 bp (fig.3).
MSC that has been transfected with the gene encoding scFv is expected to express
scFv-IgG on its cell surface, so can produce IgG. MSC is a unique multipotent stem
cell, currently widely exploited as a vector for gene therapy, including for cancer and
autoimmune diseases [8–10, 10–13].
MSC is easy to transfectionwith certain protein- coding plasmids either temporary or
long-term and stable. The transduced MSC can produce more IL-10 to produce collagen
to suppress arthritis in mouse models [15]. MSC immunoregulation also depends on
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external signals. With the presence of inflammatory cytokines or stimulants. Previous
MSC therapies have been suppressive and may become immunostimulants [16,17, 18].
4. Conclusion
The scFv gene encoding IgG can be integrated with MSC. The modified MSC to express
scFv-IgG on its cell surface is expected to respond quickly to antigen specific to scFv-
IgG. The idea for the use of MSC to express scFv-IgG against denv-1, 2, 3 and 4. Specif-
ically, the potential of MSC as an immune therapy medium is remarkable, therefore a
deep evaluation is needed for its effectiveness.
Although some studies have proven that MSC is very effective for expressing and
secreting immune therapy. Analysis of the impact of specific immunity to target organs,
including humoral and cellular responses of memory cells.
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